Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct;23(10):1721-8.
doi: 10.1007/s10552-012-0054-3. Epub 2012 Aug 24.

The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status

Sara J Schonfeld  1 , Rochelle E Curtis, William F Anderson, Amy Berrington de González
Affiliations

The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status

Sara J Schonfeld et al. Cancer Causes Control. 2012 Oct.

Abstract

Purpose: Lung cancers account for 5 % of second primary cancers after breast cancer. The low overall 5-year relative survival rate of lung cancer makes it a particularly concerning new malignancy for breast cancer survivors. It is unknown whether second lung cancer risk varies by estrogen receptor (ER) expression of the first breast cancer.

Methods: We evaluated second primary lung cancer risks using standardized incidence ratios (SIRs) (95 % confidence intervals (CIs)) among 222,148 one-year breast cancer survivors in the NCI-SEER Program registry database (1992-2008). Relative risks (RRs) and 95 % CIs for lung cancer following ER(-) compared with ER(+) breast cancer were estimated using Poisson regression, adjusted for age, year, and stage of breast cancer diagnosis, attained age, latency, and radiotherapy. We also examined the reciprocal association of second ER(-) and ER(+) breast cancers among 28,107 1-year lung cancer survivors.

Results: There were 418 and 1,444 second lung cancers diagnosed following 50,781 ER(-) and 171,367 ER(+) breast cancers. Second lung cancer rates were significantly elevated after ER(-) (SIR = 1.20 (1.09-1.33)), but not ER(+) (SIR = 0.96 (0.91-1.01)) breast cancer. The adjusted RR for a second lung cancer following ER(-) compared with ER(+) breast cancer was 1.22 (1.10-1.37). The reciprocal adjusted RR for a second ER(-) compared with ER(+) breast cancer following lung cancer was 1.29 (0.98-1.70).

Conclusion: The parallel increase for a second lung cancer following an ER(-) first breast cancer and for a second ER(-) breast cancer after a first lung cancer suggests that there may be shared etiologic factors for these cancers. Further evaluation of lung cancer risk after ER(-) breast cancer may identify women at high risk for this fatal malignancy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare that they have no conflict of interest.

References

    1. Howlader NNA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK, editors. SEER Cancer Statistics Review, 1975–2008. National Cancer Institute; Bethesda, MD: http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
    1. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12 (1):20–37. - PubMed
    1. Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev. 2007;16 (3):566–571. - PubMed
    1. Curtis RE, Ron E, Hankey BF, Hoover RN. New Malignancies Following Breast Cancer. In: Curtis RE, Freedman DM, Ron E, et al., editors. New malignancies among cancer survivors: SEER Cancer Registries, 1973–2000. National Cancer Institute. NIH Publ. No. 05-5302; Bethesda, MD: 2006. pp. 181–205.
    1. Roychoudhuri R, Evans H, Robinson D, Moller H. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer. 2004;91 (5):868–872. - PMC - PubMed

Publication types

MeSH terms

Substances